• Avaxia Biologics gets nod from FDA for investigation of new drug

Solid Phase Extraction (SPE)

Avaxia Biologics gets nod from FDA for investigation of new drug

Nov 28 2012

Avaxia Biologics Inc announced yesterday (November 27th) that the US Food and Drug Administration (FDA) has cleared the Investigational New Drug (IND) application for AVX-470.

The privately held biotechnology company develops oral antibody drugs that act locally within the digestive tract and this approval from the FDA will enable it to utilise AVX-470 in trials for the treatment of ulcerative colitis.

AVX-470 is an anti-TNF (tumour necrosis factor) polyclonal antibody and is the first clinical contender to come from the firm's oral antibody platform.

TNF is a pro-inflammatory protein that has been involved in inflammatory bowel disease (IBD), including Crohn's disease and ulcerative colitis.

A phase 1b clinical trial of AVX-470 in patients with active ulcerative colitis will be scheduled by the company in the near future.

"Clearance of the IND allows us to advance AVX-470 into clinical development, which furthers our goal of providing patients afflicted with inflammatory bowel disease with a promising new treatment option," stated Barbara S Fox, chief executive officer of the enterprise.

AVX-470 is delivered straight to the gastrointestinal (GI) tract and because of this, it has less potential for systemic immunosuppression when compared to injectable anti-TNF treatments.

At the same time, it retains the proven advantages of anti-TNF antibody therapy for inflammatory bowel disease, explained Ms Fox.

Presently, injectable anti-TNF antibodies are utilised as a successful therapy for numerous IBD sufferers, generating around £1.5 billion in sales last year.

Suppression of the immune system right through the body, not just locally in the GI tract where the disease lives, is caused by the injections - resulting in potentially dangerous side-effects.

The aim of the research investigation is to have a safer anti-TNF drug for IBD.

AVX-470 is taken orally rather than injected and is intended to stay in the GI tract where the swelling arises, rather than be dispensed throughout the body.

Posted by Ben Evans

Digital Edition

Chromatography Today - Buyers' Guide 2022

October 2023

In This Edition Modern & Practical Applications - Accelerating ADC Development with Mass Spectrometry - Implementing High-Resolution Ion Mobility into Peptide Mapping Workflows Chromatogr...

View all digital editions


NGVS 2024

May 23 2024 Beijing, China


May 28 2024 Tel Aviv, Israel


May 28 2024 Leuven, Belgium

PREP 2024

May 28 2024 Philadelphia, PA, USA


May 29 2024 Beijing, China

View all events